Trials that use: Logistic regression
New to this method? Read the tutorial →
4,487 results
- Beige Fat, Energy, and the Natriuretic Peptide System: Complete Statistical AnalysisIndependent statistical analysis of Beige Fat, Energy, and the Natriuretic Peptide System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04357964).
- BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115: Complete Statistical AnalysisIndependent statistical analysis of BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115: primary endpoint…
- Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04676360).
- Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients: Complete Statistical AnalysisIndependent statistical analysis of Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02152345).
- Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin: Complete Statistical AnalysisIndependent statistical analysis of Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin:…
- Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin’s Lymphoma(NHL): Complete Statistical AnalysisIndependent statistical analysis of Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00426855).
- Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00705250).
- Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL): Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BENEFITIndependent statistical analysis of Crossover Comparison of MultiHance and Dotarem: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02070380).
- Benefit of Assistive Listening Device for Lateralization: Complete Statistical AnalysisIndependent statistical analysis of Benefit of Assistive Listening Device for Lateralization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05072457).
- Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients: Complete Statistical AnalysisIndependent statistical analysis of Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Benzocaine Gel Toothache Dose-Response Study: Complete Statistical AnalysisIndependent statistical analysis of Benzocaine Gel Toothache Dose-Response Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00474175).
- Benzocaine Versus Placebo Spray for Pain Relief at Hysterosalpingogram: Complete Statistical AnalysisIndependent statistical analysis of Benzocaine Versus Placebo Spray for Pain Relief at Hysterosalpingogram: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01925469).
- Berinert (C1INH) vs Placebo for DGF/IRI: Complete Statistical AnalysisIndependent statistical analysis of Berinert (C1INH) vs Placebo for DGF/IRI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04696146).
- Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- BESTIndependent statistical analysis of Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Beta-Blockers in Heart Failure: Pharmacy-level Intervention Comparison: Complete Statistical AnalysisIndependent statistical analysis of Beta-Blockers in Heart Failure: Pharmacy-level Intervention Comparison: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01002456).
- BevacizumabIndependent statistical analysis of A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00401817).
- Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01125046).
- Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection: Complete Statistical AnalysisIndependent statistical analysis of Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03167411).
- BFPSIndependent statistical analysis of Home Based Peer Support Program for Mothers With Low Breastfeeding Self-efficacy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BGIndependent statistical analysis of Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01727895).
- BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size…
- BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis: Complete Statistical AnalysisIndependent statistical analysis of BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01296932).
- BIANCAIndependent statistical analysis of Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- BiBETIndependent statistical analysis of Optimized Biventricular Pacing Allograft Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01290822).
- BIBSIndependent statistical analysis of Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02188459).
- Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine: Complete Statistical AnalysisIndependent statistical analysis of Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04538040).
- Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT: Complete Statistical AnalysisIndependent statistical analysis of Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation: Complete Statistical AnalysisIndependent statistical analysis of Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy (NRT): Complete Statistical AnalysisIndependent statistical analysis of Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy (NRT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00326781).
- BIO|CONCEPT.Renamic Neo Study: Complete Statistical AnalysisIndependent statistical analysis of BIO|CONCEPT.Renamic Neo Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04350008).
- Bioavailability and Safety Study Comparing Two Dose Levels of AMZ001 and One Dose Level of Diclofenac Sodium 1% Gel in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of Bioavailability and Safety Study Comparing Two Dose Levels of AMZ001 and One Dose Level of Diclofenac Sodium 1% Gel in Healthy Participants: primary endpoint results, effect estimate with…
- BioButton Among Nursing Home Residents: Complete Statistical AnalysisIndependent statistical analysis of BioButton Among Nursing Home Residents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06665685).
- BioCSI-2Independent statistical analysis of Biomarkers of Cockroach Sublingual Immunotherapy 2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01380327).
- Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328): Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328): primary endpoint results, effect estimate with confidence interval,…
- Bioequivalence of Pramipexole Extended Release (PPX ER) 1.5mg x 1 Tablet Once Daily (q.d.) vs. PPX ER 0.375mg x 4 Tablets Under Fasted and Fed Conditions in Japanese Healthy Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence of Pramipexole Extended Release (PPX ER) 1.5mg x 1 Tablet Once Daily (q.d.) vs. PPX ER 0.375mg x 4 Tablets Under Fasted and Fed Conditions in Japanese…